Tag:
non-Hodgkin's lymphoma
Latest Headlines
Latest Headlines
UPDATED: Roche's Gazyva doubles remission time for non-Hodgkin lymphoma patients
In February, Roche said its Rituxan follow-up, Gazyva, had succeeded in a late-stage study involving non-Hodgkin lymphoma patients, extending their remission period. And it wasn't kidding.
Following a setback, Pfizer gets a win in Phase III cancer drug study
Two years after going down in flames in a Phase III study for CD22-positive non-Hodgkin's lymphoma, Pfizer has helped resurrect hopes for top drug prospect inotuzumab ozogamicin, saying the drug hit its first primary endpoint for spurring hematologic remission in patients with CD22-positive acute lymphoblastic leukemia.
Pfizer picks up the pieces after its armed antibody crashes in PhIII
Pfizer says inotuzumab failed a Phase III study for aggressive CD22+ non-Hodgkin's lymphoma. The monitoring committee concluded that inotuzumab in combination with rituximab was not going to deliver the data needed on overall survival.
Biovest bankruptcy shows travails of cancer vaccine development
The road toward developing a non-Hodgkin's lymphoma vaccine is littered with failures. Two companies, Genitope and Favrille, had trials fail in 2007 and 2008 and then quickly closed down shop. The challenges were writ large again last week when Biovest filed for bankruptcy--for the second time in 5 years.
Biovest makes a move on the EU market with BiovaxID
Biovest International's stock has risen by 15% on two pieces of news about its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, BiovaxID.
Biovest plans Canadian submission for personalized cancer vax
Biovest has chosen Canada for the first submission for approval of its personalized cancer vaccine, BiovaxID. The vaccine could become the first cancer vaccine marketed for lymphoma patients.
Lymphoma vaccine extends survival in late-stage study
In a study published in the online version of the Journal of Clinical Oncology, researchers at the University of Texas MD Anderson Cancer Center say a Phase III trial of the therapeutic vaccine
NICE approves MabThera for lymphoma maintenance
In a turnabout decision that could give sales a big boost, the U.K.'s cost-effectiveness watchdog gave Roche's MabThera a thumbs up for maintenance treatment of non-Hodgkin's lymphoma. Also known as
Cell Therapeutics shares soar on Phase III data
A late-stage study of Cell Therapeutics' pixantrone demonstrated its ability to significantly increase the remission rates of patients with non-Hodgkin's lymphoma. And investors moved swiftly to push
Biovest wants accelerated approval for anti-cancer vax
Accentia Biopharmaceuticals' subsidiary Biovest International today announced positive results from its Phase 3 Fast-Tracked clinical trial of BiovaxID for the treatment of indolent follicular
